ArticleBMC pharmacology & toxicology2025
Coenzyme Q10 microemulsion ion-activated gel: a promising ophthalmic delivery system for enhanced corneal protection and sustained release.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa.Antioxidants (Basel, Switzerland) · 2026Review
- SIRT1 Prevents Lens Epithelial Cell Senescence During Age-Related Cataract via Regulating p66Shc.Aging cell · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate a novel microemulsion ion-activated gel system for the ophthalmic delivery of coenzyme Q10 (CoQ10).
methodsVarious CoQ10 microemulsion ion-activated formulations were prepared and fully assessed for physical and chemical parameters, assay and related substances, in vitro release, rheological properties, in vitro cytotoxicity and ophthalmic retention. A preliminary pharmacokinetic study was also performed in rabbits.
resultsThe formulations met the specified criteria, showing a droplet size of 24.5 ± 2.0 nm for microemulsions, increasing slightly to 39.6 ± 3.5 nm for the microemulsion gels. They exhibited a 24-hour sustained in vitro release (80.0% ± 3.2%) and increased viscosity upon contact with artificial tears containing Ca
conclusionThis novel system is a promising preparation for ophthalmic CoQ10 delivery, offering sustained release and protection against UVB-induced corneal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.